These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12871668)

  • 1. A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity.
    Fan JQ
    Trends Pharmacol Sci; 2003 Jul; 24(7):355-60. PubMed ID: 12871668
    [No Abstract]   [Full Text] [Related]  

  • 2. A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity.
    Fan JQ
    Biol Chem; 2008 Jan; 389(1):1-11. PubMed ID: 18095864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder.
    Yam GH; Zuber C; Roth J
    FASEB J; 2005 Jan; 19(1):12-8. PubMed ID: 15629890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuning glycosidase inhibition through aglycone interactions: pharmacological chaperones for Fabry disease and GM1 gangliosidosis.
    Aguilar-Moncayo M; Takai T; Higaki K; Mena-Barragán T; Hirano Y; Yura K; Li L; Yu Y; Ninomiya H; García-Moreno MI; Ishii S; Sakakibara Y; Ohno K; Nanba E; Ortiz Mellet C; García Fernández JM; Suzuki Y
    Chem Commun (Camb); 2012 Jul; 48(52):6514-6. PubMed ID: 22618082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors.
    Fan JQ; Ishii S
    FEBS J; 2007 Oct; 274(19):4962-71. PubMed ID: 17894781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme Replacement Therapy for Lysosomal Storage Diseases.
    Kleppin S
    J Infus Nurs; 2020; 43(5):243-245. PubMed ID: 32881810
    [No Abstract]   [Full Text] [Related]  

  • 7. Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)deoxynojirimycin.
    Luan Z; Higaki K; Aguilar-Moncayo M; Ninomiya H; Ohno K; García-Moreno MI; Ortiz Mellet C; García Fernández JM; Suzuki Y
    Chembiochem; 2009 Nov; 10(17):2780-92. PubMed ID: 19830760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential action of galactose as a "chemical chaperone": increase of beta galactosidase activity in fibroblasts from an adult GM1-gangliosidosis patient.
    Caciotti A; Donati MA; d'Azzo A; Salvioli R; Guerrini R; Zammarchi E; Morrone A
    Eur J Paediatr Neurol; 2009 Mar; 13(2):160-4. PubMed ID: 18571950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological chaperone therapy for lysosomal storage disorders - leveraging aspects of the folding pathway to maximize activity of misfolded mutant proteins.
    Fan JQ
    FEBS J; 2007 Oct; 274(19):4943. PubMed ID: 17894778
    [No Abstract]   [Full Text] [Related]  

  • 10. Cyclodextrin-based iminosugar click clusters: the first examples of multivalent pharmacological chaperones for the treatment of lysosomal storage disorders.
    Decroocq C; Rodríguez-Lucena D; Ikeda K; Asano N; Compain P
    Chembiochem; 2012 Mar; 13(5):661-4. PubMed ID: 22344719
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemical chaperones: a pharmacological strategy for disorders of protein folding and trafficking.
    Perlmutter DH
    Pediatr Res; 2002 Dec; 52(6):832-6. PubMed ID: 12438657
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibitor screening of pharmacological chaperones for lysosomal β-glucocerebrosidase by capillary electrophoresis.
    Shanmuganathan M; Britz-McKibbin P
    Anal Bioanal Chem; 2011 Mar; 399(8):2843-53. PubMed ID: 21286689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond.
    Shachar T; Lo Bianco C; Recchia A; Wiessner C; Raas-Rothschild A; Futerman AH
    Mov Disord; 2011 Aug; 26(9):1593-604. PubMed ID: 21618611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies.
    Germain DP; Fan JQ
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S111-7. PubMed ID: 20040321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders.
    Desnick RJ; Schuchman EH
    Nat Rev Genet; 2002 Dec; 3(12):954-66. PubMed ID: 12459725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease.
    Yu L; Ikeda K; Kato A; Adachi I; Godin G; Compain P; Martin O; Asano N
    Bioorg Med Chem; 2006 Dec; 14(23):7736-44. PubMed ID: 16919960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological chaperones as therapeutics for lysosomal storage diseases.
    Boyd RE; Lee G; Rybczynski P; Benjamin ER; Khanna R; Wustman BA; Valenzano KJ
    J Med Chem; 2013 Apr; 56(7):2705-25. PubMed ID: 23363020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Fluorescent sp2-iminosugar with pharmacological chaperone activity for gaucher disease: synthesis and intracellular distribution studies.
    Luan Z; Higaki K; Aguilar-Moncayo M; Li L; Ninomiya H; Nanba E; Ohno K; García-Moreno MI; Ortiz Mellet C; García Fernández JM; Suzuki Y
    Chembiochem; 2010 Nov; 11(17):2453-64. PubMed ID: 21064079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor.
    Fan JQ; Ishii S; Asano N; Suzuki Y
    Nat Med; 1999 Jan; 5(1):112-5. PubMed ID: 9883849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening patients referred to a metabolic clinic for lysosomal storage disorders.
    Fuller M; Tucker JN; Lang DL; Dean CJ; Fietz MJ; Meikle PJ; Hopwood JJ
    J Med Genet; 2011 Jun; 48(6):422-5. PubMed ID: 21415080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.